Atrium Therapeutics, Inc. (RNA)
NMS · Healthcare · Biotechnology
$10.36
+0.10%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$177.2M
Shares Outstanding
17.1M
P/S (TTM)
4.9x
Exchange
NMS
Currency
USD
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 12.3M | 859K | 19.6M | 3.0M |
| Operating Income | (8.5M) | (48.0M) | (17.3M) | (22.6M) |
| Net Income | (8.3M) | (48.1M) | (16.6M) | (20.2M) |
| Diluted EPS | N/A | N/A | $-0.97 | $-1.18 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 9.8M | 10.9M | 18.6M |
| Operating Income | (6.4M) | (13.2M) | (76.8M) |
| Net Income | (6.4M) | (25.1M) | (76.7M) |
| Diluted EPS | $-0.37 | $-1.47 | $-4.48 |